BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares

Key Points

• CEO Ugur Sahin sold 36,209 BioNTech shares at an average price of $95.37, generating approximately $3.45 million. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan and reduced his direct ownership by 50%.
• Sahin has made a series of additional sales since late September, totaling hundreds of thousands of shares and several million dollars in proceeds.
• BioNTech reported weaker-than-expected quarterly results, including an EPS loss of $2.53 and revenue of $122.31 million, while analysts maintained a consensus “Moderate Buy” rating with a $125.69 target price.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the company's stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, October 8th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $92.31, for a total value of $2,492,370.00.
• On Wednesday, October 7th, Ugur Sahin sold 24,000 shares of BioNTech stock. The stock was sold at an average price of $95.86, for a total value of $2,300,640.00.
• On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total transaction of $2,033,010.00.
• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The stock was sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total value of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $4.90 during midday trading on Friday, hitting $96.96. 1,288,649 shares of the company's stock traded hands, compared to its average volume of 1,088,842. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The stock has a market capitalization of $24.52 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The firm has a fifty day moving average of $99.04 and a 200 day moving average of $95.16.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. During the same period in the previous year, the business posted ($1.60) EPS. The business's quarterly revenue was down 59.5% compared to the same quarter last year. On average, analysts forecast that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Institutional investors have recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new stake in BioNTech in the 2nd quarter worth approximately $207,142,000. Bank of America Corp DE boosted its stake in shares of BioNTech by 22.6% during the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after acquiring an additional 166,432 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after acquiring an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of BioNTech during the 2nd quarter valued at about $39,385,000. Finally, SEB Asset Management AB acquired a new stake in shares of BioNTech during the 1st quarter valued at about $17,804,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. Wall Street Zen cut shares of BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Berenberg Bank set a $140.00 price objective on BioNTech in a report on Wednesday, September 16th. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a report on Friday, October 2nd. BMO Capital Markets downgraded shares of BioNTech from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. Finally, Morgan Stanley cut their price objective on BioNTech from $115.00 to $114.00 and set an "overweight" rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $125.69.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.